U.S. government agreements with pharmaceutical giants Pfizer and Eli Lilly grant Washington revenue participation from drug sales across eight nations, including Canada. These innovative pricing arrangements represent a shift in how governments negotiate pharmaceutical costs while ensuring taxpayer investment returns. The deal structure allows the U.S. to benefit financially from drug pricing negotiations, fundamentally reshaping international pharmaceutical commerce and establishing precedent for future government-industry partnerships on medication affordability.

Summary auto-generated by AI from the original publisher's content. Editorial standards.